Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Major vascular anomalies found in brains of people with Huntington's disease

  • Genetic predisposition found for noise-induced hearing loss

  • Research Finds No Correlation between Regulatory T Cells and Survival in Glioblastoma

  • Smokers who use e-cigarettes less likely to quit, study shows

  • Adenosine receptor can activate 'off signals' for pain

  • Playing a wind instrument could help lower the risk of sleep apnea

  • Local physician recommends World Health Organization retire the term opioid substitution therapy

  • Cancer and chemobrain: Cancer diagnosis affects cognitive function

  • Forming school networks to educate 'the new mainstream'

  • Kids with ADHD must squirm to learn, study says

  •